Market research
NXS.AU Next Science Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- 0.2639
- Dividend yield
- 0.0%
- Beta
- 1.22
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU0000041329
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- 0.2639
- Dividend yield
- 0.0%
- Beta
- 1.22
About
About Next Science Limited
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NXS.AU discussion.
5 years, 5 months ago
Next Science Limited is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.
From a valuation standpoint, the stock is 78.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.4.
Next Science Limited's total revenue rose by 39.1% to $2M since the same quarter in the previous year.
Its net income has increased by 32.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Next Science Limited gets an overall score of 5/5.